Concise Review: Induced Pluripotent Stem Cell Models for Neuropsychiatric Diseases. (13th October 2017)

• Record Type: Journal Article
• Authors: Adegbola, Abidemi; Bury, Luke A.; Fu, Chen; Zhang, Meixiang; Wynshaw‐Boris, Anthony
• Is Part Of: Stem cells translational medicine. Volume 6:Number 12(2017)
• Page Start: 2062
• Page End: 2070
• Publication Date: 2017-10-13
• Subjects: Induced pluripotent stem cells -- Nervous system -- Cell biology -- Reprogramming; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.17-0150
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: The major neuropsychiatric conditions of schizophrenia, affective disorders, and infantile autism are characterized by chronic symptoms of episodic, stable, or progressive nature that result in significant morbidity. Symptomatic treatments are the mainstay but do not resolve the underlying disease processes, which are themselves poorly understood. The prototype psychotropic drugs are of variable efficacy, with therapeutic mechanisms of action that are still uncertain. Thus, neuropsychiatric disorders are ripe for new technologies and approaches with the potential to revolutionize mechanistic understanding and drive the development of novel targeted treatments. The advent of methods to produce patient‐derived stem cell models and three‐dimensional organoids with the capacity to differentiate into neurons and the various neuronal cellular lineages mark such an advance. We discuss numerous techniques involved, their applications, and areas that require further optimization. Stem Cells Translational Medicine 2017;6:2062–2070 Abstract : Patient‐derived somatic cells from a patient with neuropsychiatric disease are reprogrammed into human induced pluripotent stem cell (hiPSCs) via Yamanaka factors. Patient‐specific hiPSCs are then induced to differentiate into neural progenitor cells, neurons, and organoids.